Our Innovative Platform for Drug Development

TransCon technology combines the benefits of conventional prodrug and sustained release technologies to help solve the fundamental limitations seen in other approaches to extending duration of a drug’s action in the body. The TransCon name derives from transient conjugation, our unique ability to temporarily link an inert carrier to a parent drug with known biology to achieve sustained release.

About TransCon
About TransCon

TransCon Prodrugs Have Three Components

A parent drug with known biology
A known linker that temporarily binds the parent drug to an inert carrier
A known carrier that inactivates and shields the parent drug from clearance
The three components allow us to design TransCon prodrugs with predictable release of the unmodified parent drug to achieve the desired dosing frequency and pharmacological effect

TransCon

A flexible platform that can be applied to various types of parent drugs and that can be tailored to achieve different dosing and release profiles

Click to enlarge image

Sustained Systemic Release

When injected, physiological conditions initiate sustained release of the active, unmodified parent drug at a predictable rate

Click to enlarge image

References: 1. Thornton PS, et al. J Clin Endocrinol Metab. 2021;106(11):3184-3195. 2. Zúñiga LA, et al. Cancer Cell Int. 2022;22(1):286. 3. Breinholt VM, et al. Br J Clin Pharmacol. 2022;884:4763-4772. 4. Ascendis Pharma A/S. Form 20-F. Accessed May 28, 2025. SEC FILING | Ascendis Pharma.